These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 22227528)

  • 1. New generation small-molecule inhibitors in myeloproliferative neoplasms.
    Passamonti F; Maffioli M; Caramazza D
    Curr Opin Hematol; 2012 Mar; 19(2):117-23. PubMed ID: 22227528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. JAK inhibitors: pharmacology and clinical activity in chronic myeloprolipherative neoplasms.
    Treliński J; Robak T
    Curr Med Chem; 2013; 20(9):1147-61. PubMed ID: 23317159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JAK2 inhibitors and their impact in myeloproliferative neoplasms.
    Geyer HL; Tibes R; Mesa RA
    Hematology; 2012 Apr; 17 Suppl 1():S129-32. PubMed ID: 22507800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting myeloproliferative neoplasms with JAK inhibitors.
    Pardanani A; Tefferi A
    Curr Opin Hematol; 2011 Mar; 18(2):105-10. PubMed ID: 21245760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic potential of JAK2 inhibitors.
    Verstovsek S
    Hematology Am Soc Hematol Educ Program; 2009; ():636-42. PubMed ID: 20008249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.
    Quintás-Cardama A; Vaddi K; Liu P; Manshouri T; Li J; Scherle PA; Caulder E; Wen X; Li Y; Waeltz P; Rupar M; Burn T; Lo Y; Kelley J; Covington M; Shepard S; Rodgers JD; Haley P; Kantarjian H; Fridman JS; Verstovsek S
    Blood; 2010 Apr; 115(15):3109-17. PubMed ID: 20130243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations.
    Pardanani A; Vannucchi AM; Passamonti F; Cervantes F; Barbui T; Tefferi A
    Leukemia; 2011 Feb; 25(2):218-25. PubMed ID: 21079613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors.
    Choong ML; Pecquet C; Pendharkar V; Diaconu CC; Yong JW; Tai SJ; Wang SF; Defour JP; Sangthongpitag K; Villeval JL; Vainchenker W; Constantinescu SN; Lee MA
    J Cell Mol Med; 2013 Nov; 17(11):1397-409. PubMed ID: 24251790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual PI3K/AKT/mTOR inhibitor BEZ235 synergistically enhances the activity of JAK2 inhibitor against cultured and primary human myeloproliferative neoplasm cells.
    Fiskus W; Verstovsek S; Manshouri T; Smith JE; Peth K; Abhyankar S; McGuirk J; Bhalla KN
    Mol Cancer Ther; 2013 May; 12(5):577-88. PubMed ID: 23445613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN).
    Isfort S; von Bubnoff N; Al-Ali HK; Becker H; Götze T; le Coutre P; Griesshammer M; Moskwa C; Wohn L; Riedel J; Palandri F; Manz K; Hochhaus A; Döhner K; Heidel FH
    Ann Hematol; 2024 Aug; 103(8):2775-2785. PubMed ID: 38967662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms.
    Tibes R; Bogenberger JM; Benson KL; Mesa RA
    Mol Diagn Ther; 2012 Oct; 16(5):269-83. PubMed ID: 23023734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of JAK1/2 inhibitors in the treatment of chronic myeloproliferative neoplasms.
    Keohane C; Mesa R; Harrison C
    Am Soc Clin Oncol Educ Book; 2013; ():301-5. PubMed ID: 23714529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breakthroughs in myeloproliferative neoplasms.
    Santos FP; Verstovsek S
    Hematology; 2012 Apr; 17 Suppl 1():S55-8. PubMed ID: 22507780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Janus kinase inhibitors for the treatment of myeloproliferative neoplasms.
    Rosenthal A; Mesa RA
    Expert Opin Pharmacother; 2014 Jun; 15(9):1265-76. PubMed ID: 24766055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms.
    Bogani C; Bartalucci N; Martinelli S; Tozzi L; Guglielmelli P; Bosi A; Vannucchi AM;
    PLoS One; 2013; 8(1):e54826. PubMed ID: 23382981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Janus kinase inhibitors: an update on the progress and promise of targeted therapy in the myeloproliferative neoplasms.
    Stein BL; Crispino JD; Moliterno AR
    Curr Opin Oncol; 2011 Nov; 23(6):609-16. PubMed ID: 21993415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms.
    Tyner JW; Bumm TG; Deininger J; Wood L; Aichberger KJ; Loriaux MM; Druker BJ; Burns CJ; Fantino E; Deininger MW
    Blood; 2010 Jun; 115(25):5232-40. PubMed ID: 20385788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JAK2 inhibitors for myelofibrosis: why are they effective in patients with and without JAK2V617F mutation?
    Santos FP; Verstovsek S
    Anticancer Agents Med Chem; 2012 Nov; 12(9):1098-109. PubMed ID: 22583424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of related JAK/STAT pathways with molecular targeted drugs shows strong synergy with ruxolitinib in chronic myeloproliferative neoplasm.
    Barrio S; Gallardo M; Arenas A; Ayala R; Rapado I; Rueda D; Jiménez-Ubieto A; Albizua E; Burgaleta C; Gilsanz F; Martinez-Lopez J
    Br J Haematol; 2013 Jun; 161(5):667-676. PubMed ID: 23560534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New JAK2 inhibitors for myeloproliferative neoplasms.
    Quintás-Cardama A; Verstovsek S
    Expert Opin Investig Drugs; 2011 Jul; 20(7):961-72. PubMed ID: 21521147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.